What question did this study set out to answer?

To determine the prevalence, clinical associations, and therapeutic management of anaemia across a broad population of patients with inflammatory bowel disease.

January 1, 2016Digestion

Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study

View Full Paper

Ask AI

Bookmark

Authors

FPFrancisco Portela PLPaula Lago JCJosé Cotter

Discussion

Member takes

Overview

Cross-sectional multicenter study observes anaemia in 18.6% of patients with inflammatory bowel disease, indicating widespread undertreatment particularly among those with active disease.

Key Points

To determine the prevalence, clinical associations, and therapeutic management of anaemia across a broad population of patients with inflammatory bowel disease.
Conducted an observational cross-sectional multicentre study across 15 participating centres during a 1-month period.
Enrolled 1,313 adult patients with inflammatory bowel disease, comprising Crohn's disease (59%), ulcerative colitis (39%), and unclassified disease (2%).
Evaluated disease activity using the Harvey-Bradshaw Index for Crohn's disease and the Simple Clinical Colitis Activity Index for ulcerative colitis.
Anaemia prevalence was 18.6% (95% CI 16.6–20.9; 244 of 1,313 patients), with 90% presenting with mild to moderate anaemia (mean haemoglobin 11.3 ± 0.8 g/dL) and higher frequency in females (p = 0.006).
Anaemia was significantly more frequent in patients with active disease compared to remission (33.6% vs. 15.6%, p < 0.001) and in those taking corticosteroids (36.8% vs. other therapies, p < 0.001), with no difference between Crohn's disease (19.1%) and ulcerative colitis (17.7%; p = 0.688).
Only 47% of anaemic patients received specific therapy, consisting of oral iron in 67% and intravenous iron in 41% of treated cases.

Cite This Study

Portela et al. (2016) studied this question.

synapsesocial.com/papers/6aa921135349ab3cd2263530 https://doi.org/10.1159/000443927

View Full Paper

Ask AI

Bookmark

January 1, 2016Digestion

Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study

View Full Paper

Ask AI

Bookmark

Authors

FPFrancisco Portela PLPaula Lago JCJosé Cotter

Discussion

Member takes

Overview

Cross-sectional multicenter study observes anaemia in 18.6% of patients with inflammatory bowel disease, indicating widespread undertreatment particularly among those with active disease.

Key Points

To determine the prevalence, clinical associations, and therapeutic management of anaemia across a broad population of patients with inflammatory bowel disease.
Conducted an observational cross-sectional multicentre study across 15 participating centres during a 1-month period.
Enrolled 1,313 adult patients with inflammatory bowel disease, comprising Crohn's disease (59%), ulcerative colitis (39%), and unclassified disease (2%).
Evaluated disease activity using the Harvey-Bradshaw Index for Crohn's disease and the Simple Clinical Colitis Activity Index for ulcerative colitis.
Anaemia prevalence was 18.6% (95% CI 16.6–20.9; 244 of 1,313 patients), with 90% presenting with mild to moderate anaemia (mean haemoglobin 11.3 ± 0.8 g/dL) and higher frequency in females (p = 0.006).
Anaemia was significantly more frequent in patients with active disease compared to remission (33.6% vs. 15.6%, p < 0.001) and in those taking corticosteroids (36.8% vs. other therapies, p < 0.001), with no difference between Crohn's disease (19.1%) and ulcerative colitis (17.7%; p = 0.688).
Only 47% of anaemic patients received specific therapy, consisting of oral iron in 67% and intravenous iron in 41% of treated cases.

Cite This Study

Portela et al. (2016) studied this question.

synapsesocial.com/papers/6aa921135349ab3cd2263530 https://doi.org/10.1159/000443927

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark